snp genotyping assay massarray assay design 3.1 (Sequenom)
90
Structured Review
Sequenom
snp genotyping assay massarray assay design 3.1
Snp Genotyping Assay Massarray Assay Design 3.1, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/snp+genotyping+assay+massarray+assay+design+3%2E1/snp+genotyping+assay+massarray+assay+design+3+1/pm29869121-39-20-27
Average 90 stars, based on 1 article reviews
Snp Genotyping Assay Massarray Assay Design 3.1, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/snp+genotyping+assay+massarray+assay+design+3%2E1/snp+genotyping+assay+massarray+assay+design+3+1/pm29869121-39-20-27
Average 90 stars, based on 1 article reviews
snp genotyping assay massarray assay design 3.1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Mutagenesis:Article Title: Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Article Snippet: Background To investigate the clinicopathological features and prognostic significance of the BRAFV600E mutation in Asian patients with colorectal cancer.. Methods We retrospectively reviewed the medical records of 1969 patients with colorectal cancer admitted to Taipei Veterans General Hospital for surgical treatment between 2000 and 2013.. The measured endpoint was overall survival after surgery. SNP Genotyping Assay:Article Title: Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Article Snippet: Background To investigate the clinicopathological features and prognostic significance of the BRAFV600E mutation in Asian patients with colorectal cancer.. Methods We retrospectively reviewed the medical records of 1969 patients with colorectal cancer admitted to Taipei Veterans General Hospital for surgical treatment between 2000 and 2013.. The measured endpoint was overall survival after surgery. |